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  EVIDENCE-BASED ANSWER 
There is insufficient evidence to advocate the routine use of folate supplementation for the treatment of 
coronary artery disease (CAD). High levels of serum homocysteine have been associated in several studies 
with an increased risk for CAD (strength of recommendation [SOR]: B, associated in case-control studies). 
Folate supplementation decreases the level of serum homocysteine (SOR: A, meta-analysis of randomized 
controlled trials). This indirect evidence suggests that folate supplementation may be of benefit in slowing the 
progress of arteriosclerosis. 
Two randomized controlled trials measuring the clinical benefits of folate supplementation for patients with 
CAD have been completed, with differing results. One study showed no benefit of 0.5 mg/d of folate for 
patients with stable CAD already on statin therapy. The other study found that patients given 1 mg/d of folate 
with vitamins B6 and B12 had a decreased restenosis rate after percutaneous coronary intervention (PCI) (SOR: 
B, conflicting randomized controlled trials). 
It is possible that larger doses of folate are needed to be of clinical benefit, or that the addition of vitamins B6 
and B12 are needed for synergy. Several randomized control trials are underway to further assess folate’s 
affect on CAD. 
  EVIDENCE SUMMARY 
Hyperhomocysteinemia is defined as a fasting plasma homocysteine level 15 μmol/L, although levels >10 
μmol/L appear to have detrimental effects on risk profiles for CAD and arteriosclerosis.1 In 22 of 27 
retrospective case-control studies, patients with CAD had significantly higher plasma homocysteine levels than 
control subjects (odds ratio [OR]=1.2–10.9, after adjustment for other CAD risk factors).2,3 However, only 4 of 7 
prospective nested case-control trials showed a correlation between elevated homocysteine and myocardial 
infarction (MI) and coronary death.2 
A meta-analysis of 12 randomized controlled trials found that folate supplementation, with vitamin B6 and B12, 
reduces plasma homocysteine levels.4 However, the long-term clinical cons quences of these interventions are 
unknown. At doses of 1 gm/d folate has no known side-effects.5 
Two randomized, placebo-controlled trials of folate reporting clinical endpoints have been completed. One 
study analyzed folate supplementation in a patient population with known, stable CAD and found no difference 
in clinical endpoints at 24 months.6 In this study, 593 patients were randomized to receive either 0.5 mg/d of 
folic acid or placebo. The primary study endpoint was a composite of events including: overall mortality, 
sudden death, MI, stroke, and major vascular surgery. The study was powered to detect a 50% reduction in 
clinical events based on existing observational data in populations with CAD. An event rate of 15% for the 2-
year interval was assumed.6 All patients in this study were on statin therapy prior to initiation of folate 
supplementation. 
The second study analyzed folate supplementation in 553 post-PCI patients. Patients were treated with 1 mg of 
folate plus 10 mg of vitamin B6 and 400 μg of vitamin B12 for 6 months after the PCI. After a mean follow-up of 
11 months, the rate of restenosis requiring revascularization was lower in the vitamin-treated study arm (9.9% 
vs 16% restenosis rate; relative risk [RR]=0.62; 95% confidence interval [CI], 0.40–0.97; number needed to 
treat=16).7 There was also a nonsignificant trend toward fewer deaths and MIs in the treated arm at both 6 and 
12 months after intervention (death: 1.5% vs 2.8%; RR=0.54; 95% CI, 0.016–1.7; MI: 2.6% vs 4.3%; RR=0.60; 
95% CI, 0.24–1.51). Statin use was similar in both control (71%) and treatment groups (69%). 
  RECOMMENDATIONS FROM OTHERS 
The American Heart Association and American College of Cardiology do not recommend the routine use of 
high-dose folic acid or B-vitamin supplements for the primary or secondary prevention of cardiovascular 
events. The AHA recommendation is to meet recommended daily allowances of folate (400 μg), B12 (2.4 μg), 
and B6 (1.7 mg) primarily through a balanced diet, with use of supplements if diet alone does not meet the 
above requirements.8 Since 1998, wheat flour has been supplemented with folate, adding an estimated 100 
μg/day to the average American diet.8 
The Canadian Task Force on Preventive Health Care (CTFPHC) finds insufficient evidence to advocate 
screening for hyperhomocysteinemia and rely on expert opinion to advocate treatment in select, high-risk 
populations.2 Currently, the CTFPHC advocates meeting the recommended daily allowance of folate, B12, and 
B6.2 
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Folate for CAD an unanswered question 
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Folate seems like a simple, inexpensive, and relatively benign way to improve care. It is 
no wonder that many physicians have been recommending folate to their patients with 
CAD for years. However, as responsible physicians, we need more comprehensive 
evidence on the benefit of folate before making such universal recommendations. 
Several points are important: first, most of the evidence on folate is from observational 
studies. Only 1 interventional study has shown benefit for patients with CAD, and this 
study used folate in combination with vitamins B6 and B12. Therefore, if physicians are 
going to recommend folate supplementation to their patients with CAD, they should 
recommend this combination rather than folate alone. Also, since this study only included 
patients who are post-PTCA, it may not apply to all patients with CAD. In short, there is 
still a fair amount of uncertainty in the answer to this clinical question. We should discuss 
this uncertainty with our patients, and come to a mutual decision based on preferences. 
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